Navigation Links
Foul-smelling gas shows health benefits in reducing joint swelling
Date:4/29/2013

A gas associated with the smell of rotten eggs has proven to effectively reduce joint swelling, in research which could lead to advances in the treatment of arthritis.

Scientists at the University of Exeter Medical School have discovered that a novel drug molecule, which slowly generates the gas hydrogen sulfide (H2S), effectively reduces swelling and inflammation in arthritic joints.

For years, H2S has been regarded as a highly poisonous by-product which is corrosive, flammable and explosive. But research is now showing an altogether more benign side to the substance.

Professor Matt Whiteman, of the University of Exeter Medical School, said the research, which is published online in the Journal of Cellular and Molecular Medicine, could pave the way for more effective treatments of arthritis and other inflammatory conditions. Prof Whiteman said: "H2S is widely dismissed as a toxic and foul-smelling environmental pollutant, but it has recently been shown to be created in humans and animals by a specific set of enzymes. Why would the body do this if it had no benefit? Our research has shown that the key to unlocking the therapeutic qualities of H2S is through slow release, mimicking the body's own production."

The team has previously shown that H2S levels were increased by up to four times in the knee joints of patients with joint diseases such as rheumatoid arthritis, but intriguingly the higher H2S levels strongly correlated with a lower number of inflammatory cells in the joint. The latest study provides further evidence that the real role for H2S may be to combat inflammation, swelling and joint destruction.

Prof Whiteman added: "A patient will usually visit their doctor with a joint already inflamed, swollen and painful. Since the compound worked after arthritis was established, it may be useful in treating arthritis in the future. Many compounds can prevent arthritis in the laboratory, but of course nobody knows when they will get arthritis. Having a class of compounds which reduce inflammation and swelling when arthritis is already active is extremely exciting. These molecules may also be useful in other inflammatory conditions, and even in the inflammatory aspects of diabetes and obesity."

The study was part of a large collaboration funded by the Wellcome Trust and Arthritis Research UK, involving Professor Philip K Moore and Dr Julie Keeble from King's College London, as well as researchers at the National University of Singapore and Queen's University, Belfast. The team used primary human cells as well as a model of arthritis. Rheumatoid arthritis causes some cells to proliferate too quickly in the joint and secrete substances which promote tissue inflammation, swelling and eventually joint destruction. However, the H2S donor molecule prevented this secretion, and inhibited the activity of several enzymes which cause inflation. In the arthritis model, the compound did not prevent arthritis, but was highly effective at reducing joint inflammation and swelling once arthritis was established, suggesting H2S-based compounds may one day be useful in clinic.

The same team has previously found that people who are overweight or have diabetes have lower levels of H2S in their bodies than healthy adults resulting in higher blood pressure, poorer insulin sensitivity and higher levels of sugar in their blood. It has also been reported to promote ulcer healing and reduce lung injury in smokers.

Co-author Dr Mark E Wood, at the University of Exeter, added: "Despite its reputation for being hazardous, H2S could in fact hold the key to solving some of the widespread health problems affecting the country. Our work is a major step in proving that it can be more hero than villain to the human body, providing it is administered in the right way, at the right time. We currently have several more efficient H2S donor molecules being evaluated with collaborators and this is a very exciting time for us."

Dr Julie Keeble, co-author from King's College London, commented: "The finding that H2S is able to reduce joint inflammation in experimental models makes it a very exciting prospect for treating arthritis. Many patients with arthritis do not respond effectively to current treatments or suffer side-effects from their medication. We hope that H2S-releasing drugs like the one tested in this study will be effective in treating arthritis without uncomfortable side effects."


'/>"/>

Contact: Louise Vennells
l.vennells@exeter.ac.uk
44-013-927-24927
University of Exeter
Source:Eurekalert

Related medicine news :

1. Wellesley study shows income inequality a key factor in high US teen births
2. Invasive heart test being dramatically overused, Stanford study shows
3. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
4. Lung Cancer Screening Might Pay Off, Analysis Shows
5. Nonsurgical Method to Measure Brain Pressure Shows Promise
6. BMC study shows diverting passengers to elevators could help reduce falls at Logan Airport
7. Study Shows New Option for Kids With Tough-to-Treat Leukemia
8. Politics May Get in the Way of Empathy, Research Shows
9. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
10. Experimental Pill for Multiple Sclerosis Shows Promise
11. Mechanical tissue resuscitation technology shows promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The TouchPoint Solution, home of Buzzies ... stress and anxiety. , “Buzzies change the way we interact with stress and ... , Since its launch date in December 2016, The TouchPoint Solution has sold more ...
(Date:3/23/2017)... ... , ... ?This conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... , 43rd President of the United States of America: George W. Bush , ... Out of the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber ...
(Date:3/23/2017)... ... 23, 2017 , ... It’s that time of year again! Time to think ... summer internships , which can be frustrating when they don’t even know how to ... a boutique public relations firm outside of Philadelphia, have offered these three tips to ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... skincare products, was awarded as winners of American Dreams & Good Housekeeping Seal ... hosted jointly by HSN and Good Housekeeping. , Steven Wang, MD ., ...
(Date:3/23/2017)... , ... March 23, 2017 , ... News Advisory/Interview Opportunity ... has helped score a major victory in Europe for public health and the environment ... , Based on rigorous scientific research and the overwhelming support of European citizens, the ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology: